Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PCSK9s: Discount Prompts NICE Turnaround on Sanofi's Praluent

Executive Summary

HTA body NICE has Okayed PCSK9 inhibitors Repatha and Praluent for adults with primary hypercholesterolaemia or mixed dyslipidaemia for use on the National Health Service IN England and Wales. However, restrictions on prescribing will likely limit sales.

You may also be interested in...



Discounts Sway NICE As Novartis Outlines Concerns Over New Cancer Drugs Fund

NICE – the HTA body for England and Wales – has recommended that Novartis's Zykadia (ceritinib) be available on the NHS, but only at a discount. Novartis tells Scrip that with the imminent arrival of the UK's new Cancer Drugs Fund (CDF), there are concerns that access to new cancer drugs will become even more difficult.

Amgen's Harper Says Repatha Is Priced Right

The things that keep Sean Harper up at night have changed over the last few years as science has advanced and the drug development landscape has changed. Harper, who is the head of R&D at big biotech Amgen Inc., once worried that his company wouldn't be able to keep up, now he's concerned with where the money is going to come from.

Amgen Earnings Beat Expectations; Company Pushing Payers On Repatha

Amgen Inc.'s first quarter revenue and earnings beat consensus estimates without a meaningful contribution from sales of the cholesterol-reducing biologic Repatha (evolocumab), but the company is pushing back against payers that are denying reimbursement to appropriate patients.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC065121

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel